tbuckley/cabot-search huggingface dataset:
First-line treatment with rituximab combined with intravenous or oral fludarabine for patients with extranodal mucosa associated lymphoid tissue (MALT) lymphoma
Authors: A. Salar, E. Domingo-Domenech, C. Estany, M. Canales, C. Montalban
Journal: Journal of Clinical Oncology (2008)

8608 Background: The addition of rituximab to other drugs has improved outcomes in several types of NHL without a significant addition of toxicity. Our aim was to evaluate the safety and efficacy of rituximab combined with fludarabine in first-line therapy for extranodal MALT lymphoma. Methods: This study enrolled adult patients with untreated extranodal MALT lymphoma who were candidate to receive systemic treatment. Patients received rituximab 375 mg/m2 intravenously (IV) on day 1 and fludarabine 25 mg/m2 (IV) given on days 1–5 (days 1–3 in > 60 years), every 4 weeks; after the first cycle, oral fludarabine was allowed to be given orally at 40 mg/m2 with the same schedule. After three cycles, a work-up was done. Patients in CR received an additional cycle and, if PR, a total of 6 cycles was recommended. Use of G-CSF and prophylactic antibiotics was optional. Results: 22 patients have been included and started on therapy. Characteristics of the first 18 pts: median age: 59 years (range: 32–83); 7 male, 11 female; PS 0 (94%); site of lymphoma origin: stomach (61%), skin (16%), lung (11%), parotid gland (11%); stage: I (66%), II (16%) and IV (16%). A total of 82 cycles of R-F were administered; 2 pts received 2 cycles, 9 pts 4 cycles, 7 pts 6 cycles. 17 pts are evaluable for response. Overall response rate was 100% with 94% achieving CR. One pt relapsed. Median follow-up from starting treatment is 15 m (range: 17–27). PFS rate is 93% (CI95%: 79–100%) at 12 m and OS rate is 100% at 12 m. Tolerance to oral fludarabine was excellent with most patients preferring this formulation. Mild neutropenia was the most common toxicity, usually presenting after the third cycle. No blood transfusions were required. 3 pts developed grade 2 respiratory infection, but none pt had to be admitted. Conclusions: These preliminary data indicate that the RF regimen, either with intravenous or oral fludarabine, was well tolerated even in elderly patients. This combination is very active for the treatment of untreated extranodal MALT lymphoma, even with fewer cycles than initially planned. Updated data will be presented. No significant financial relationships to disclose.
Peripheral blood transcriptomics-based molecular predictors of breast cancer.
Authors: E. M. Blanchard, S. Domhan, L. Ma, C. Schwager, S. Ambika, L. A. Martin, J. Debus, P. J. Hesketh, L. Hlatky, A. Abdollahi
Journal: Journal of Clinical Oncology (2010)

e21018 Background: There is an unmet need for molecular predictors of early breast cancer. We hypothesized that gene expression as measured by peripheral blood mRNA profiles might distinguish women with early stage invasive (but nonmetastatic) breast cancer (IBC), ductal carcinoma in situ (DCIS), and healthy volunteers (V). Methods: Sixty-one patients (pts) have been accrued (24 IBC, 17 DCIS, 20 V). Pt characteristics are presented in the Table. Peripheral blood was collected and RNA conserved from pts using PAX-gene system. After depletion of globin mRNA genome-wide expression profiles were generated using Illumina platform from peripheral blood samples of 36 pts (the identification set: 16 IBC, 10 DCIS, 10 V). The remaining samples are used as a validation set. Microarray data analysis and statistics were performed using SUMO software. Results: Our data indicate that perturbation of the peripheral blood transcriptome could be detected at the earliest stage of tumor development ie, DCIS. The predominant expression pattern identified by statistical tests and cluster analysis distinguished V from DCIS/IBC. We found 88 genes that distinguished between V and DCIS, 99 between V and IBC, but only 14 to be differentially regulated in DCIS vs. IBC (p<0.001). Using leave-three-out cross- validation analysis the expression of 33 genes was found to predict breast cancer vs. healthy volunteers with high sensitivity (∼90%) and specificity (>95%). In this “breast cancer signature,” genes associated with key carcinogenesis pathways such as SDFR1 and PIK3AP1 were found to be upregulated in the peripheral blood of breast cancer pts. The predictive value of the identified 33 gene set as well as selected genes are the subject of q-RT-PCR confirmation analysis in the identification and validation collective and will be presented at the Meeting. Conclusions: We demonstrate here the feasibility of the blood transcriptome as a sentinel organ for detection of breast cancer at its earliest (ie DCIS) stage. This discovery of novel blood based molecular predictors of breast cancer has the potential to improve breast cancer screening and consequently treatment outcome. IBC Ductal 92% Stage I 58 Stage II 42 Node + 25 ER+ 96 HER2+ 13 DCIS Grade Low 24% Int 24 High 53 ER+ 65 No significant financial relationships to disclose.
The Case for Neurological Network Diseases
Authors: Hannah Machemehl, Dala Eloubeidi, Hassan Fathallah-Shaykh
Journal: JAMA Neurology (2016)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Neurology HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Neurology journal
Fractionated High-Dose Cyclophosphamide and G-CSF: An Extremely Effective Chemo-Mobilization Modality In Patients With Multiple Myeloma
Authors: Ahmad Antar, Zaher K. Otrock, Nadim El Majzoub, Nabila Kreidieh, Muhammad Muhammad, Rami Mahfouz, Mohamed A. Kharfan-Dabaja, Ali Bazarbachi
Journal: Blood (2013)
Chromosome Analysis of a Spontaneous, Transplantable Golden Hamster Tumor
Authors: M. Nachtigal
Journal: JNCI Journal of the National Cancer Institute (1965)

The chromosome constitution of nine “H 10” golden hamster sarcomas was analyzed. The distribution of chromosome counts in 845 metaphases revealed a diploid stemline. This represented an average of 66 percent of the dividing cell population. With the use of the easily recognizable X chromosome as a cytological marker, it was determined that the diploid and near-diploid cells originated in the host and did not grow in a homologous animal. The analysis of 84 karyotypes showed the existence of pseudodiploidy and chromosomal changes in some of the diploid and near-diploid cells. The polyploid cells had a mode of 85–102, predominantly 96 chromosomes, and were characterized by a high number of X chromosomes. These cells with similar chromosome constitution were considered to be serially transferred from animal to animal, and it was thought that the large number of X chromosomes might give a selective advantage for transplantation. The high proportion of diploid and near-diploid cells in all tumors examined is discussed and viral induction of growth in the host animal is suggested.
The prognostic value of EGFR Sp1–216 gene polymorphism in locally advanced rectal cancer treated with preoperative chemoradiation
Authors: K. G. Spindler, J. Lindebjerg, J. Ploen, A. Jakobsen
Journal: Journal of Clinical Oncology (2008)

4123 Background: Development of preoperative chemoradiation (CRT) followed by surgery have reduced the rate of local recurrences in locally advanced rectal cancer, but some patients still die from distant metastasis. Selection of high risk patients, who might benefit from adjuvant chemotherapy, is important, and reliable prognostic markers in this setting are crucial. We evaluated the prognostic value of a new polymorphism in the promoter region of the EGFR gene, (Sp1–216), which is potentially related to the outcome of chemoradiation and can be identified in a blood sample. Methods: One-hundred-and-thirty-three patients were treated with preoperative CRT (external total dose of 60 Gy by 5-field conformal technique, ± an intracavitary fraction of 5 Gy to the tumour bed) and concomitant oral Uftoral (Merck KGaA, Darmstadt, Germany) 300mg/m2 daily and Leukovorin 22.5mg/per day five days a week. Genomic DNA was extracted from whole blood and genotype analysis was performed by PCR using the ABI PRISM 7900 HT Sequence Detection System and results were verified by sequencing. Cancer specific survival was calculated from the time of surgery to death of colorectal cancer or last follow-up. The prognostic value of different parameters was analysed using the Kaplan Mayer methods with log-rank test for comparison of groups. Results: The median follow-up was 26 month (12–94 mos). Fourteen patients died during the observation period, and 12 were cancer related deaths. The cancer specific survival rate was 82%. Only 55% of patients with the EGFR Sp1–216 TT genotype were alive compared to 87% and 88%, of the G/G and G/T patients (p<0.01), indicating a poor prognosis of patients with the T/T genotype. Statistical analysis suggested that the Sp1–216 genotype is an independent prognostic factor in this setting. Conclusions: EGFR Sp1–216 genotyping, performed on a blood sample, could provide important prognostic information in this setting and further studies are warranted. No significant financial relationships to disclose.
Use of nuclear androgen receptor status to predict early biochemical recurrence of prostate cancer patients
Authors: J. Diallo, A. Aldejmah, M. Alam Fahmy, I. Koumakpayi, A. Mes-Masson, F. Saad
Journal: Journal of Clinical Oncology (2007)

21073 Background: Prostate cancer (PCa) is a leading cause of cancer death in North American men. The androgen receptor (AR) has an established role in the progression of this disease; however, it is unclear at what stage it intervenes. It is also uncertain whether the AR can be a useful prognostic marker for PCa. In this study, we assessed AR expression and sub-cellular localization in normal prostate as well as in androgen sensitive and insensitive PCa (AIPCa) tissues, and evaluated the ability of the AR to predict biochemical recurrence (BCR). Methods: We used tissue micro-arrays containing prostate tissue cores obtained from cancer-free patients (n=43), AIPCa patients (n=36), and patients with hormone-sensitive cancers (n=64) from which were collected both cancerous and normal adjacent tissue. Using immmunohistochemistry, we stained the tissue micro-arrays with a monoclonal antibody recognizing the AR. Two observers assessed the frequency and intensity of both cytoplasmic and nuclear AR staining. AR cytoplasmic (Ci) and nuclear (Ni) indices were calculated by multiplying nuclear staining frequency and nuclear staining intensity. Kaplan Meier, and Cox multivariate analyses were done using SPSS. Results: We found that AR Ci increased significantly in AIPCa although a modest but significant increase in PCa Ci was observed compared to normal tissues. In contrast, AR Ni was significantly lower in cancer-free patients as opposed to that seen in normal tissue adjacent to cancer. Similarly, cancerous tissue exhibited higher AR Ni than its adjacent normal tissue (p&lt;0.05, Kruskal-Wallis). Kaplan Meier analyses revealed that low AR Ni was predictive of an early onset of BCR (before 3-years) in the sub-cohort of hormone-sensitive patients (LR=6.51, p=0.011). Futhermore, low AR Ni remained an independent predictor of early BCR in a Cox multivariate model controlling for age, pre-operative PSA, lymph node invasion, Gleason score and surgical margin status (HR=2.28, 95% CI=1.04 - 5, p&lt;0.05). Conclusions: We conclude that increased nuclear AR activity could be a pre-malignant step in PCa progression whereas its role within cancer cells may be more complex, as low AR nuclear activity was associated with early onset of BCR. No significant financial relationships to disclose.
Association of Serum Lipids and Coronary Heart Disease in Contemporary Observational Studies
Authors: Lisandro D. Colantonio, Vera Bittner, Kristi Reynolds, Emily B. Levitan, Robert S. Rosenson, Maciej Banach, Shia T. Kent, Stephen F. Derose, Hui Zhou, Monika M. Safford, Paul Muntner
Journal: Circulation (2015)

The use of statins increased among US adults with high coronary heart disease (CHD) risk after publication of the 2001 cholesterol treatment guidelines.
Abstract 14759: Molecular Imaging of Activated Factor XIII for Early Detection of Coronary Microvascular Disease in Mice
Authors: Zhen W Zhuang, Rong Ju, Mark W Maxfield, Xiangning Wang, Michael Simons, Albert J Sinusas
Journal: Circulation (2012)

Background: Coronarary microvascular disease (MVD) remains a major clinical problem affecting women twofold more than men, and involves endothelial dysfunction and microthrombosis. We hypothesized ...
A survey of Canadian medical oncologists on internet use for medical information and a needs assessment for an oncology education website
Authors: S. Verma, L. Horn, J. Chung, S. Vijayaratnam, S. Berry
Journal: Journal of Clinical Oncology (2007)

17072 Background: The internet offers an innovative resource for medical oncologists to share and discuss important medical information and advances. Despite the existence of many websites with oncology related information, there has not been a comprehensive assessment of how Canadian medical oncologists use the internet to access this information. Purpose: In the first phase of developing a new educational website (OncologyEducation.com), we surveyed Canadian medical oncologists to determine how they used the internet to access information and to assess their needs for a web based educational resource. Method: A structured survey was developed and assessed for face and content validity by medical oncologists from our local institution. The survey had several domains including: comfort level with computers, description of internet use for work, and key features they would want in an educational website. The survey was sent to all medical oncologists in Canada via regular mail and e-mail. Results: 58 % (144/247) of medical oncologists responded to our survey. The number of years in practice varied from &lt;5 yrs (31%) to 5–10 yrs (30%), and 11–20 years (15%) with 85% having an academic appointment. 90% of respondents were comfortable with using a computer. The most common reasons for internet use were email (91%), literature updates (78%), and answering clinical questions (72%). 27% of respondents used the internet for clinical questions daily, and 29% on a weekly basis. 49% accessed the internet for work-related information for 1–5 hours weekly, 26% for 6–10 hours weekly, and 20% for more than 11hrs weekly. Respondents expressed a need for an educational website stressing the following content: (1) Canadian Oncologists Database to improve opportunities for collaboration (2) Key updates by disease sites (3) Access to information about upcoming conferences. Conclusion: The internet plays a major role in the daily clinical activities of Canadian medical oncologists. The development of an education website based on the needs assessed in this survey is warranted. We are currently developing this site (OncologyEducation.com) and plan to evaluate on an ongoing basis. No significant financial relationships to disclose.
Clinical implication of neuroendocrine differentiation (NED) in non-small-cell lung cancer (NSCLC)
Authors: Y. Segawa, A. Ogino, N. Nogami, T. Shinkai, R. Nishimura, N. Teramoto, E. Komori, S. Sawada, M. Yamashita, S. Takashima
Journal: Journal of Clinical Oncology (2008)

22174 Background: Although NED has been detected by immunohistochemical or ultrastructual studies in 10% to 20% of histologically ordinary NSCLCs, clinical feature of NSCLC with NED is not well understood. In this prospective study, we assessed clinical implication of NED in NSCLC. Methods: The NED was determined based on immunoexpression of four neuroendocrine markers, i.e., chromogranin A (CGA), synaptophysin (SP), NCAM, and Leu7, in consecutively bronchoscopically-biopsied NSCLC specimens. Results: 280 subjects were entered to this study between April 2004 and March 2006. Of those, 245 were diagnosed with lung cancer; 150 were diagnosed using bronchoscopically-biopsied specimens; and 129 pts with ordinary NSCLC were included in this analysis (19 with small- cell lung cancer, 1 with cartinoid, and 1 with small specimen not enough to conduct immunostaining were excluded). The proportion of pts with NSCLC that had immunoexpression for at least one of four neuroendocrine markers was 16% (21/129 pts); according to histological subclassification, 27% (15/55 pts) for adenocarcinoma, 8% (4/50 pts) for squamous cell carcinoma, and 8% (2/24 pts) for NSCLC not otherwise specified, respectively. Treatment consisted of surgical resection in 43 pts and non-surgical approaches in 73 pts (chemotherapy, n = 37; thoracic radiotherapy, n = 17; chemoradiotherapy, n = 19). For pts receiving non-surgical approaches, proportion of responders was 70% (7/10 pts) in NED-positive group and 51% (32/63 pts) in NED-negative group, respectively (p = 0.25). At a median follow-up time of 18.6 months (range, 0.5–39.3 months), median progression-free survival was 7.7 months in NED-positive group and 5.5 months in NED-negative group, respectively (p = 0.44). In addition, although overall survival did not reach to median value in NED-positive group, median overall survival in NED-negative group was 15.3 months (p = 0.13). Significant difference between NED in NSCLC and treatment outcome was not confirmed in a multivariate analysis. Conclusions: There was no difference between immunoixpression of NED in NSCLC and treatment outcome for pts receiving non-surgical approaches in this study. Result for pts receiving surgical resection will be presented at the meeting. No significant financial relationships to disclose.
Venous central line catheter management in respiratory semi-intensive care unit: The way to zero central line-associated bloodstream infections (CLABSIs) – A randomized controlled trial
Authors: Riccardo Inchingolo, Andrea Smargiassi, Giuliana Pasciuto, Giuseppe Corbo, Manuela Cavalletti, Giuliano Montemurro, Daniele Magnini, Giancarlo Scoppettuolo, Riccardo Torelli, Teresa Spanu, Maurizio Sanguinetti, Salvatore Valente
Journal: European Respiratory Journal (2014)

Aims: 1) efficacy of educational interventions on rate of CLABSIs, 2) effects of port protector, 3) rate of contamination.

9months of observation and 9months of interventional period. We enrolled patients with CVC: 1) placed in RSICU, 2) previously placed without signs of SIRS during 48h before of admittance, 3) previously placed without microbiological evidence of colonization.

During interventional period we randomized patients into two groups: 1) educational intervention plus port protector (Group 1) and 2) educational intervention (Group 2). Patients developing SIRS underwent both peripheral and central blood cultures. We identified 5 conditions: 1) CVC-related sepsis (both blood cultures positive with differential time to CVC positivity at least 2h before); 2) CVC not related sepsis (both blood cultures positive with: a) differential time to CVC positivity less than 2h or b) peripheral positivity precedes CVC one); 3) CVC colonization; 4) contamination of peripheral blood culture; 5) central and peripheral blood cultures negativity.

87 CVC were included during observational period. Catheter dwell time was 1068. CLABSIs rate was 8.4/1000. 10 sepsis (9 CLABSIs), 16 CVC colonization and 6 contamination of blood cultures were observed. 46 CVC were included during interventional period. Catheter dwell time was 707. CLABSIs rate was 1.4/1000. 21/46 CVC were included into Group 1. 5 CVC colonization (2 in Group 1), 3 contamination of blood cultures (only in Group 2) were observed. In Group 1 no CLABSIs were reported.

Both kinds of interventions significantly reduce the rate of CLABSIs.
Phase I Study of the Aurora A Kinase Inhibitor Alisertib in Combination With Irinotecan and Temozolomide for Patients With Relapsed or Refractory Neuroblastoma: A NANT (New Approaches to Neuroblastoma Therapy) Trial
Authors: Steven G. DuBois, Araz Marachelian, Elizabeth Fox, Rachel A. Kudgus, Joel M. Reid, Susan Groshen, Jemily Malvar, Rochelle Bagatell, Lars Wagner, John M. Maris, Randall Hawkins, Jesse Courtier, Hollie Lai, Fariba Goodarzian, Hiroyuki Shimada, Scarlett Czarnecki, Denice Tsao-Wei, Katherine K. Matthay, Yael P. Mosse
Journal: Journal of Clinical Oncology (2016)

Purpose Alisertib is an oral Aurora A kinase inhibitor with preclinical activity in neuroblastoma. Irinotecan and temozolomide have activity in patients with advanced neuroblastoma. The goal of this phase I study was to determine the maximum tolerated dose (MTD) of alisertib with irinotecan and temozolomide in this population. Patients and Methods Patients age 1 to 30 years with relapsed or refractory neuroblastoma were eligible. Patients received alisertib tablets at dose levels of 45, 60, and 80 mg/m 2 per day on days 1 to 7 along with irinotecan 50 mg/m 2 intravenously and temozolomide 100 mg/m 2 orally on days 1 to 5. Dose escalation of alisertib followed the rolling six design. Samples for pharmacokinetic and pharmacogenomic testing were obtained. Results Twenty-three patients enrolled, and 22 were eligible and evaluable for dose escalation. A total of 244 courses were administered. The MTD for alisertib was 60 mg/m 2 , with mandatory myeloid growth factor support and cephalosporin prophylaxis for diarrhea. Thrombocytopenia and neutropenia of any grade were seen in the majority of courses (84% and 69%, respectively). Diarrhea in 55% of courses and nausea in 54% of courses were the most common nonhematologic toxicities. The overall response rate was 31.8%, with a 50% response rate observed at the MTD. The median number of courses per patient was eight (range, two to 32). Progression-free survival rate at 2 years was 52.4%. Pharmacokinetic testing did not show evidence of drug-drug interaction between irinotecan and alisertib. Conclusion Alisertib 60 mg/m 2 per dose for 7 days is tolerable with a standard irinotecan and temozolomide backbone and has promising response and progression-free survival rates. A phase II trial of this regimen is ongoing.